Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

SNPX

Synaptogenix Inc

May 10 • 04:00PM ET

4.57

Dollar change -0.14
Percentage change -2.97	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF

Index	-	P/E	-	EPS (ttm)	-43.39	Insider Own	3.24%	Shs Outstand	1.09M	Perf Week	-10.22%
Market Cap	4.98M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.05M	Perf Month	-5.28%
Income	-13.78M	PEG	-	EPS next Q	-	Inst Own	5.03%	Short Float	2.87%	Perf Quarter	-6.76%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.56	Perf Half Y	-32.55%
Book/sh	25.27	P/B	0.18	EPS next Y	-	ROA	-17.32%	Short Interest	0.03M	Perf Year	-77.29%
Cash/sh	27.61	P/C	0.17	EPS next 5Y	-	ROE	-21.17%	52W Range	3.53 - 47.00	Perf YTD	-32.77%
Dividend Est.	-	P/FCF	-	EPS past 5Y	8.59%	ROI	-56.59%	52W High	-90.28%	Beta	1.51
Dividend TTM	-	Quick Ratio	7.14	Sales past 5Y	0.00%	Gross Margin	-	52W Low	29.55%	ATR (14)	0.47
Dividend Ex-Date	-	Current Ratio	7.14	EPS Y/Y TTM	-113.06%	Oper. Margin	0.00%	RSI (14)	47.20	Volatility	8.06% 9.10%
Employees	8	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	3.00	Target Price	350.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	-108.10%	Payout	-	Rel Volume	0.54	Prev Close	4.71
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	53.60K	Price	4.57
SMA20	-1.30%	SMA50	-3.19%	SMA200	-39.27%	Trades		Volume	28,909	Change	-2.97%

May-07-24 09:00AM	Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery (PR Newswire)
Apr-24-24 09:15AM	Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire)
Apr-09-24 09:15AM	Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics (PR Newswire) -8.35%
Apr-03-24 08:00AM	Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing (PR Newswire)
Dec-19-23 09:00AM	Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders (PR Newswire) +5.45%
09:00AM	Loading…
Dec-06-23 09:00AM	Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's (PR Newswire)
Nov-02-23 09:00AM	Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology (PR Newswire)
Sep-26-23 09:00AM	Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease (PR Newswire) +5.67%
Sep-07-23 09:00AM	Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study (PR Newswire) -12.23%
Jul-19-23 09:00AM	Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis (PR Newswire)
Jul-13-23 09:00AM	Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience (PR Newswire) +20.79%
Mar-07-23 09:00AM	Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities (PR Newswire)
Dec-16-22 09:00AM	Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease (PR Newswire) -74.63%
Nov-18-22 09:00AM	Synaptogenix Announces $15 Million Private Placement with Existing Investors (PR Newswire) +12.72%
Oct-19-22 09:00AM	Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022 (PR Newswire)
11:50AM	Loading…
Sep-28-22 11:50AM	Synaptogenix Welcomes Lecanemab Phase 3 Trial Results (PR Newswire)
Aug-12-22 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire) +5.10%
Jul-26-22 09:15AM	Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data (PR Newswire) +6.37%
Jul-21-22 09:15AM	Synaptogenix Announces Corporate Update Conference Call (PR Newswire)
Jul-20-22 09:15AM	Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data (PR Newswire) +5.81%
May-17-22 09:15AM	Synaptogenix to Present at the Cell Symposium (PR Newswire) +10.97%
Apr-19-22 09:15AM	Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial (PR Newswire) -5.69%
Apr-05-22 09:15AM	New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease (PR Newswire)
Mar-29-22 09:15AM	Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit (PR Newswire)
Mar-22-22 09:15AM	Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum (PR Newswire)
Mar-15-22 09:15AM	Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022) (PR Newswire)
Feb-23-22 09:15AM	Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis (PR Newswire)
Feb-07-22 09:38AM	Orion Capital Management LLC Buys Qualcomm Inc, Distillate U.S. ... (GuruFocus.com) -5.88%
Feb-01-22 09:15AM	Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients (PR Newswire) +29.36%
Dec-06-21 11:58AM	We're Hopeful That Synaptogenix (NASDAQ:SNPX) Will Use Its Cash Wisely (Simply Wall St.)
09:00AM	Loading…
Sep-28-21 09:00AM	Synaptogenix Announces Participation at the Benzinga Healthcare Small Cap Conference (PR Newswire)
Sep-10-21 09:00AM	Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference (PR Newswire)
Aug-05-21 10:00AM	Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome (PR Newswire) -6.18%
Jul-26-21 09:15AM	Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021 (PR Newswire) -19.09%
Jul-21-21 09:00AM	Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings (PR Newswire) +19.86%
Jul-14-21 09:00AM	Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline (PR Newswire) +9.74%
Jul-07-21 09:00AM	Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease (PR Newswire) -13.16%
Jun-24-21 09:00AM	Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network (PR Newswire)
Jun-14-21 09:00AM	Synaptogenix Announces $12.5 Million Private Placement (PR Newswire)
Jun-09-21 09:00AM	Synaptogenix Announces Phase 2b NIH Sponsored Alzheimer's Disease Trial Update (PR Newswire)
05:38AM	Is Synaptogenix (NASDAQ:SNPX) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
May-19-21 09:00AM	Synaptogenix Announces Plan to Uplist on the Nasdaq Stock Market (PR Newswire)
May-10-21 09:00AM	Synaptogenix, Inc: Invitation to the Benzinga Global Small Cap Conference (Newsfile) -12.50%
Apr-26-21 09:00AM	Synaptogenix to Present at Sachs 4th Annual Neuroscience Innovation Forum (PR Newswire) +7.60%
Apr-01-21 09:00AM	Synaptogenix Announces Phase 2b Bryostatin-1 Clinical Trial Update (PR Newswire)
Mar-05-21 09:00AM	Synaptogenix to Present at the H.C. Wainwright Global Life Sciences Conference (PR Newswire) -8.16%
Feb-25-21 09:12AM	Synaptogenix to Present at Upcoming Scientific Industry Conferences (PR Newswire)
Feb-12-21 09:00AM	Synaptogenix to Participate in the Winter Wonderland - Best Ideas from the Buy-Side Conference (PR Newswire)
Feb-09-21 09:00AM	Synaptogenix Files Application to List on the Nasdaq Stock Market (PR Newswire) +20.83%

Synaptogenix, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of Bryostatin and Platform Drug used for the treatment of Alzheimer's disease, Fragile X Syndrome or Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. The company was founded on October 31, 2012 and is headquartered in New York, NY.

Open in Screener

XWEL

XWELL Inc

May 10 • 04:00PM ET

1.82

Dollar change -0.05
Percentage change -2.67	%

Healthcare • Diagnostics & Research • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VXF VTI

Index	-	P/E	-	EPS (ttm)	-6.65	Insider Own	2.96%	Shs Outstand	4.18M	Perf Week	1.68%
Market Cap	7.61M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.06M	Perf Month	22.97%
Income	-27.74M	PEG	-	EPS next Q	-	Inst Own	7.23%	Short Float	1.78%	Perf Quarter	20.77%
Sales	30.11M	P/S	0.25	EPS this Y	-	Inst Trans	-	Short Ratio	5.39	Perf Half Y	7.06%
Book/sh	3.11	P/B	0.59	EPS next Y	-	ROA	-50.71%	Short Interest	0.07M	Perf Year	-63.28%
Cash/sh	5.51	P/C	0.33	EPS next 5Y	20.00%	ROE	-104.83%	52W Range	1.26 - 6.40	Perf YTD	4.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	66.28%	ROI	-127.87%	52W High	-71.56%	Beta	2.42
Dividend TTM	-	Quick Ratio	2.75	Sales past 5Y	124.62%	Gross Margin	5.37%	52W Low	44.44%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	2.85	EPS Y/Y TTM	8.37%	Oper. Margin	-63.65%	RSI (14)	58.00	Volatility	8.18% 8.19%
Employees	337	Debt/Eq	0.85	Sales Y/Y TTM	-46.18%	Profit Margin	-92.14%	Recom	1.00	Target Price	7.00
Option/Short	No / Yes	LT Debt/Eq	0.67	EPS Q/Q	51.28%	Payout	-	Rel Volume	0.75	Prev Close	1.87
Sales Surprise	1.23%	EPS Surprise	0.00%	Sales Q/Q	-2.05%	Earnings	Apr 16 AMC	Avg Volume	13.38K	Price	1.82
SMA20	11.25%	SMA50	4.65%	SMA200	-22.20%	Trades		Volume	9,966	Change	-2.67%

May-02-24 08:00AM	XpresSpa Introduces IV Hydration Drip Therapy at Miami International Airport (GlobeNewswire)
Apr-19-24 09:00AM	XWELL Inc (XWEL) Q4 2023 Earnings Call Transcript Highlights: Strategic Expansions and Cost ... (GuruFocus.com)
Apr-17-24 08:48AM	XWELL, Inc. (NASDAQ:XWEL) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-16-24 11:52PM	XWEL Stock Earnings: XWELL Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:30PM	XWELL, Inc. Reports Fiscal Year 2023 Results (GlobeNewswire)
08:00AM	Loading…
08:00AM	XWELL, Inc. to Report Fiscal Year 2023 Financial Results on Tuesday, April 16, 2024 (GlobeNewswire)
Apr-01-24 04:30PM	XWELL, Inc. Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K (GlobeNewswire)
Mar-12-24 07:01AM	CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago (PR Newswire)
Feb-14-24 08:00AM	XWELL Advances Expansion Plan Outside the Airport with Three New Naples Wax and Skin Care Locations (GlobeNewswire) +11.18%
Jan-04-24 08:00AM	XWELL Announces Plans to Open an XpresSpa in THE PENN DISTRICT (GlobeNewswire)
Dec-15-23 04:15PM	XWELL Appoints Veteran Consumer & Wellness Entrepreneur Ga lle Wizenberg to its Board of Directors (GlobeNewswire)
Dec-11-23 08:00AM	XpresSpa Introduces Clockwork Robotic Manicures at Harry Reid International Airport in Las Vegas (GlobeNewswire)
Nov-15-23 08:00AM	XWELL Opens New XpresSpa Location in Abu Dhabi International Airport (GlobeNewswire)
Nov-14-23 04:30PM	XWELL, Inc. Reports Third Quarter 2023 Results (GlobeNewswire) +5.93%
Nov-06-23 07:06AM	US CDC to expand surveillance of travelers for respiratory viruses (Reuters)
07:00AM	Loading…
07:00AM	Ginkgo Bioworks and XWELL Implement Expanded CDC Traveler-based Genomic Surveillance Program to Test for More than 30 Known Pathogens (PR Newswire)
Oct-11-23 08:00AM	XWELL Unveils New Corporate Identity and Enhanced Website for its Leading Airport Spa Brand, Xpres Spa (GlobeNewswire) -6.47%
Oct-09-23 08:00AM	XWELL's CEO Scott Milford Discusses Strategic Growth Plans During Recent Investor Fireside Chat (GlobeNewswire)
Oct-02-23 08:00AM	XWELL Celebrates Breast Cancer Awareness Month with Philanthropic Nail Care Program (GlobeNewswire)
Sep-28-23 09:00AM	XWELL s CEO Scheduled to Present at Upcoming Investor Fireside Chat on October 4, 2023 (GlobeNewswire) -10.77%
Sep-27-23 08:00AM	XWELL, Inc. Announces 1-for-20 Reverse Stock Split (GlobeNewswire) -25.40%
Sep-19-23 08:00AM	XWELL Introduces New Stretch Service at XpresSpa (GlobeNewswire)
Sep-12-23 04:30PM	XWELL Grows Footprint Outside the Airport with Acquisition of Naples Wax Center (GlobeNewswire) +8.43%
Aug-19-23 08:02AM	XWELL, Inc. (NASDAQ:XWEL) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-17-23 08:08AM	XWELL Extends Collaboration with Centers for Disease Control and Preventions Traveler-Based Genomic Surveillance Program (GlobeNewswire)
Aug-15-23 06:23AM	Q2 2023 XWELL Inc Earnings Call (Thomson Reuters StreetEvents) -10.87%
Aug-14-23 04:30PM	XWELL, Inc. Reports Second Quarter 2023 Results (GlobeNewswire)
Aug-07-23 04:30PM	XWELL, Inc. to Announce Second Quarter 2023 Financial Results on Monday, August 14 (GlobeNewswire)
Jul-20-23 08:00AM	XpresSpa Debuts Clockwork Robotic Manicures at Miami International Airport (GlobeNewswire)
Jul-18-23 04:15PM	XWELL Unveils XWELL Rewards Loyalty Program (GlobeNewswire) +18.32%
11:22AM	Loading…
Jul-14-23 11:22AM	Here's Why We're A Bit Worried About XWELL's (NASDAQ:XWEL) Cash Burn Situation (Simply Wall St.) -5.56%
Jul-13-23 08:00AM	XWELL, Inc. Appoints Suzanne Scrabis as Chief Financial Officer (GlobeNewswire) +12.50%
May-16-23 05:54AM	Q1 2023 XWELL Inc Earnings Call (Thomson Reuters StreetEvents)
May-15-23 04:30PM	XWELL, Inc. Reports First Quarter 2023 Results (GlobeNewswire)
May-11-23 12:39PM	Hey Redditors! Its Time to Dump MULN Stock Before It Falls Below $1. (InvestorPlace)
08:00AM	XWELL, Inc. to Announce First Quarter 2023 Financial Results on Monday, May 15 (GlobeNewswire)
May-04-23 08:00AM	XWELL, Inc. Names Valerie Lightfoot Chief Financial Officer (GlobeNewswire) +9.01%
May-03-23 08:00AM	XWELL Unveils Automated Massage Chairs at XpresSpa Locations Across the U.S. (GlobeNewswire)
Apr-27-23 04:15PM	XWELL, Inc. Granted 180-Day Extension by NASDAQ to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire) -10.45%
Apr-19-23 03:54PM	Revenues Working Against XWELL, Inc.'s (NASDAQ:XWEL) Share Price (Simply Wall St.)
Apr-18-23 06:35AM	Q4 2022 XWELL Inc Earnings Call (Thomson Reuters StreetEvents) -7.93%
Apr-17-23 04:15PM	XWELL, Inc. Reports Fiscal Year 2022 Results (GlobeNewswire) +5.22%
Apr-14-23 05:05PM	XWELL, Inc. to Announce 2022 Financial Results on Monday April 17 (GlobeNewswire)
Mar-30-23 04:30PM	XWELL Announces Plans to File Form 12b-25 to Extend Filing Date of its Form 10-K And Provides Preliminary FY2022 Operating Update (GlobeNewswire)
Mar-22-23 08:00AM	First Robot Manicure Unveiled at XpresSpa at John F. Kennedy International Airport (GlobeNewswire)
Jan-31-23 08:00AM	XWELL to Participate in Water Tower Fireside Chat Series (GlobeNewswire)
Jan-17-23 08:00AM	Ginkgo Bioworks and XpresCheck Expand CDCs Traveler-Based Genomic Surveillance Program to Detect Influenza Variants (GlobeNewswire)
Dec-20-22 09:11AM	12 Penny Stocks With Biggest Upside (Insider Monkey)
Dec-12-22 08:00AM	XWELL Chief Executive Officer Issues Letter to Shareholders Regarding the Companys Operating Strategy (GlobeNewswire)
Dec-05-22 08:00AM	XWELL to Bring State of the Art Technology to XpresSpa and Treat Locations in Partnership with HydroMassage® and Human Touch® (GlobeNewswire)
Nov-16-22 05:20AM	XWELL Third Quarter 2022 Earnings: US$0.076 loss per share (vs US$0.053 profit in 3Q 2021) (Simply Wall St.) -9.60%
Nov-10-22 04:00PM	XWELL, Inc. Reports Third Quarter 2022 Results (GlobeNewswire)
Nov-09-22 08:00AM	XWELL Increases International Footprint with Five New XpresSpa Locations at Istanbul International Airport (GlobeNewswire) -5.22%
Nov-07-22 08:00AM	XWELL to Bring Robotic Manicures to US Airports Through New Partnership with Clockwork (GlobeNewswire) -6.61%
Nov-03-22 06:00PM	XWELL, Inc. to Announce Third Quarter 2022 Financial Results on Thursday, November 10 (GlobeNewswire)
Nov-02-22 04:00PM	XWELL Celebrates Opening of New Treat Location at Salt Lake City International Airport (GlobeNewswire)

XWELL, Inc. provides global travel health and wellness services. It operates through the following segments: XpresSpa, XpresTest, Naples Wax Center, Treat, and Corporate & Other. The XpresSpa segment offers travelers premium spa services, including massage, nail and skin care, as well as spa and travel products. The XpresTest segment deals with diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public. The Naples Wax Center segment is focused on the products and service offerings from face and body waxing to a range of skincare and cosmetic products. The Treat segment is a wellness brand that provides access to wellness services for travelers at on-site centers. The company was founded by Jonathan Medved and David Goldfarb on January 9, 2006 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WEINSTEIN ROBERT	Director	May 30 '23	Buy	0.25	25,000	6,175	156,485	May 31 08:32 AM
WEINSTEIN ROBERT	Director	May 26 '23	Buy	0.25	25,000	6,250	131,485	May 30 08:34 AM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SNPX

Synaptogenix Inc

XWEL

XWELL Inc

Upgrade your FINVIZ experience